Eosinophilic Esophagitis

Eosinophilic esophagitis (EoE) is a chronic, local, immune-mediated, inflammatory disease localized in the esophagus.1

EoE is characterized by eosinophilic inflammation, which is thought to be triggered by exposure to aero- or food allergens, and can lead to esophageal dysfunction.1,2

Eosinophilic esophagitis illustration

Epidemiology

The incidence and prevalence of eosinophilic esophagitis have steadily increased over time. Approximately 1 in 2000 people in the U.S. live with EoE.2,3 EoE is often accompanied by other comorbidities, and has a strong association with atopic disease.1,4,5 Clinicians should maintain a high index of suspicion of EoE, regardless of age, race or sex; however, EoE is approximately twice as common in men vs women and more common among White people, with symptoms varying by age.6

Diagnosis

The diagnosis of EoE is dependent on clinical, endoscopic, and histologic findings. These findings include symptoms of esophageal dysfunction; endoscopic findings of rings, furrows, exudates, edema, stricture, narrowing, and crepe-paper mucosa; and eosinophilic infiltration, which is defined as ≥15 eosinophils per high power field (eos/hpf) on an esophageal biopsy, that is isolated to the esophagus.7 A diagnosis of EoE is not reliant on prior response to proton pump inhibitors (PPIs). EoE should be suspected if a patient presents with chronic signs and symptoms of esophageal dysfunction such as: dysphagia, food impaction, food refusal, failure to progress with food introduction, heartburn, regurgitation, vomiting, chest pain, odynophagia, abdominal pain and malnutrition.

Pathophysiology

The pathophysiology of EoE involves the production of pro-inflammatory cytokines that promote the recruitment and proliferation of immune effector cells, such as eosinophils, at the site of inflammation. This chronic inflammation, localized to the esophagus can disrupt normal epithelial integrity.2,8,9 If left untreated, the disease can progress to a fibrostenotic phenotype with esophageal remodeling and dysmotility.1,10,11

Navigating EoE

The symptoms and impact of EoE can vary by age.1,12 Infants and toddlers with EoE may experience vomiting, food refusal, choking with meals, and sleep disturbances. Children may experience dysphagia, choking and gagging with certain foods, food impactions, pain, nausea and vomiting, sleep disturbances, and decreased appetite. Adults may report dysphagia, food impaction, food avoidance, intractable heartburn, regurgitation, and chest pain. Surveys of patients with EoE suggest their greatest concerns relate to difficulty swallowing and the overall impact on eating.13,14 Symptomatic improvement has been shown to be a key endpoint of therapy.15,16

Medication Resources

Eohilia

(budesonide oral suspension)

Upcoming & Past Conferences in Gastroenterology

  • Upcoming

  • Past

European Society for Clinical Nutrition & Metabolism Congress (ESPEN), 2024

September 7 - 10, 2024 | Link to Event

Annual global congress dedicated to clinical nutrition and metabolism, including basic and clinical research, education, and organization of consensus statements about clinical care.

United European Gastroenterology Week (UEGW), 2024

October 12 - 15, 2024 | Link to Event

Global congress for researchers from around the world to present their findings on gastroenterology and digestive health.

American College of Clinical Pharmacy (ACCP), 2024

October 12 - 15, 2024 | Link to Event

Annual event dedicated to excellence in clinical pharmacy practice, research, and education.

Academy of Managed Care Pharmacy Nexus (AMCP Nexus), 2024

October 14 - 17, 2024 | Link to Event

Annual event with more than 2,500 members and non-members of the AMCP to engage on the latest innovations and most intentional networking in managed care pharmacy.

American College of Allergy, Asthma & Immunology (ACAAI), 2024

October 24 - 28, 2024 | Link to Event

Global meeting featuring thought leaders from around the world focused on advancing patient care in allergy and immunology.

American College of Gastroenterology (ACG), 2024

October 25 - 30, 2024 | Link to Event

Premier event for clinicians and the general public about digestive disorders and the latest trends in GI technology and therapeutics.

North American Society For Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN), 2024

November 6 - 9, 2024 | Link to Event

Annual forum for participants to learn about the latest advances in pediatric gastroenterology, hepatology, and nutrition, and to discuss current topics in clinical applications.

Advances in Inflammatory Bowel Diseases (AIBD), 2024

December 9 - 11, 2024 | Link to Event

An all-encompassing event providing real-world clinical education, case studies and new evidence-based approaches in IBD management.

Digestive Disease Week (DDW), 2024

May 18 - 21, 2024

Global meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Professional Society for Health Economics and Outcomes Research (ISPOR), 2024

May 5 - 8, 2024

Leading global conference discussing how to establish, incentivize, and share value sustainable for health systems, patients, and technology developers.

Academy of Managed Care Pharmacy (AMCP), 2024

April 15 - 18, 2024

Large assembly of pharmacy and healthcare professionals dedicated to the issues of managed care pharmacy, offering immersive education sessions and keynote presentations.

Campaign Urging Research for Eosinophilic Disease (CURED), 2024

April 4 - 7, 2024

International meeting concerning the field of Eosinophilic Gastrointestinal Disorders, including EoE and other eosinophilic diseases.

  • Improved Histopathologic Features in Patients with Eosinophilic Esophagitis: Data from a Phase 3, Randomized, Placebo-Controlled Trial of Budesonide Oral Suspension

American Society for Parenteral and Enteral Nutrition (ASPEN), 2024

March 2 - 5, 2024

Annual global conference for interdisciplinary, clinical nutrition leaders, providing the latest in clinical nutrition research, education, and products.

Annual Meeting American Academy of Allergy Asthma and Immunology (AAAAI), 2024

February 23 - 26, 2024

Premier global educational event for allergists and immunologists, with thousands of attendees each year, discussing allergies, asthma, and immune deficiency disorders.

European Crohn's and Colitis Organisation

February 21 - 24, 2024

Annual global congress structured around basic science, traditional medicine and clinical sessions given by some of the world's top GI specialists.

Crohn's & Colitis Congress (CCC), 2024

January 25 - 25, 2024

Annual conference for a multidisciplinary community of practitioners and researchers focusing on inflammatory bowel disease (IBD) by pairing best practices in clinical care with innovative research.

Advances in Inflammatory Bowel Diseases (AIBD), 2023

December 14 - 16, 2023

An all-encompassing event providing real-world clinical education, case studies and new evidence-based approaches in IBD management.

Entyvio® (vedolizumab)

  • Biologic Therapy Sequencing in Ulcerative Colitis: A Real-World Observational Study of Second-Line Therapy After Vedolizumab

American College of Gastroenterology (ACG), 2023

October 20 - 25, 2023

Premier event for clinicians and the general public about digestive disorders and the latest trends in GI technology and therapeutics.

Entyvio® (vedolizumab)

  • Response Trajectory by the Clinical Decision Support Tool Probability Groups in Vedolizumab-Treated Patients With Crohn’s Disease: A Pooled Analysis of GEMINI 2, VISIBLE 2, and VERSIFY
  • Number Needed to Treat to Maintain Clinical Remission with Advanced Therapies in Patients with Moderate to Severe Ulcerative Colitis
  • Vedolizumab Long-Term Treatment Persistence and Safety – Results From a Multinational Extended Access Program Study
  • Corticosteroid-Free Remission in Anti-TNF-Failed Crohn’s Disease Patients Treated With Vedolizumab as Second-Line Biologic Therapy: A Real-World Data Review
  • Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Bio-Naïve Patients With Late Crohn’s Disease: Results From the EVOLVE Expansion Study
  • Healthcare Resource Utilization and Costs Across Different Sequences of Advanced Therapies in Patients with Crohn’s Disease or Ulcerative Colitis

Motegrity® (prucalopride)

  • Efficacy and safety of prucalopride in patients with chronic idiopathic constipation from different racial and ethnic groups: a post hoc analysis of phase 3 and 4 clinical study data

Academy of Managed Care Pharmacy Nexus (AMCP Nexus), 2023

October 16 - 19, 2023

Annual event with more than 2,500 members and non-members of the AMCP to engage on the latest innovations and most intentional networking in managed care pharmacy.

  • Costs and Patient Characteristics Associated With High Versus Low Healthcare Resource Utilization in Patients With Inflammatory Bowel Disease: a Real-World Study in the USA

United European Gastroenterology Week (UEGW), 2023

October 14 - 17, 2023

Global congress for researchers from around the world to present their findings on gastroenterology and digestive health.

Entyvio® (vedolizumab)

  • Machine Learning-Based Precision Medicine Approach Identifies Specific Responder Sub-Populations by Dynamic Clustering of PRO Data: Post Hoc Analysis of VARSITY Dataset
  • High-dimensional single-cell analysis identifies cellular signature associated with response to vedolizumab therapy in ulcerative colitis
  • Corticosteroid-Free Remission in Anti-TNF-Failed Crohn’s Disease Patients Treated With Vedolizumab as Second-Line Biologic Therapy: A Real-World Data Review
  • Vedolizumab Long-Term Treatment Persistence And Safety – Results From A Multinational Extended Access Programme Study

North American Society For Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN), 2023

October 4 - 7, 2023

Annual forum for participants to learn about the latest advances in pediatric gastroenterology, hepatology, and nutrition, and to discuss current topics in clinical applications.

Gattex® (teduglutide)

  • Teduglutide Long-Term Safety and Effectiveness for a Pediatric Cohort Enrolled in an Observational, Prospective, Multi-Center Short Bowel Syndrome and Intestinal Failure Registry

European Society for Clinical Nutrition & Metabolism Congress (ESPEN), 2023

September 11 - 14, 2023

Annual global congress dedicated to clinical nutrition and metabolism, including basic and clinical research, education, and organization of consensus statements about clinical care.

American Neurogastro­enterology and Motility Society (ANMS), 2023

August 11 - 13, 2023

Annual meeting uncovering cutting-edge research ranging from basic neurogastroenterology, translational and clinical aspects of gastrointestinal motility, and functional disorders.

Motegrity® (prucalopride)

  • Prescription medication use in chronic idiopathic constipation in the USA from the healthcare professional perspective: a retrospective observational study
  • Management of chronic idiopathic constipation in US patients from the healthcare professional perspective: a retrospective observational study

Congress of the Intestinal Rehabilitation and Transplant Association (CIRTA), 2023

June 30 - July 3, 2023

Bi-annual congress promoting intestinal rehabilitation and transplantation as a safe, innovative science involving nutritional, medical, surgical and transplant therapies through education, policy development and research.

Gattex® (teduglutide)

  • Long-term safety analysis of teduglutide treatment in adult patients with short bowel syndrome and intestinal failure (SBS-IF): analysis from a prospective, multinational registry